赵亮,官志忠
ZHAO Liang,GUAN Zhizhong

• 1:贵州医科大学微生物学教研室
• 2:贵州医科大学附院病理科
• 3:贵州医科大学地方病与少数民族性疾病教育部重点实验室
• 4:贵州省医学分子生物学重点实验室贵州医科大学

摘要(Abstract)：

目的:观察洛伐他汀对过表达APP670/671的人神经母细胞瘤SH-SY5Y细胞活性及β-淀粉样蛋白(Aβ)二聚体合成的影响。方法:转染并鉴定过表达APP670/671的SH-SY5Y细胞,筛选无细胞毒性、不影响细胞胆固醇水平浓度的洛伐他汀处理SH-SY5Y细胞24 h,采用CCK-8试验检测细胞的存活率,蛋白印迹法检测Aβ二聚体的蛋白表达水平。结果:过表达APP670/671的SH-SY5Y细胞中APP的蛋白及mRNA表达水平均明显高于野生型细胞;用0.1μmol/L的洛伐他汀处理SH-SY5Y细胞,未见明显细胞毒性作用,胆固醇水平亦未见明显改变;0.1μmol/L洛伐他汀预处理SH-SY5Y细胞24 h,能提高细胞存活率,减少Aβ二聚体的分泌。结论:洛伐他汀具有神经保护作用,可能与减少毒性Aβ的合成有关。
Objective:To observe the effect of lovastatin on APP670/671 gene over-expressed human neuroblastoma SH-SY5 Y cell activity and the synthesis of dimer of beta amyloid protein(Aβ).Methods:The human APP670/671 gene was transfected into the SH-SY5 Y cells and identified.The best concentration of lovastatin which had no cell toxicity and did not affect the cell cholesterol concentration was screened,which treated SH-SY5 Y cells for 24 h.Then,CCK-8 test was used to detect the cell survival rate,and Western blot was adopted to detect the protein expression level of Aβ dimer.Results:The protein and mRNA levels of APP in SH-SY5 Y/APPSWE cells were obviously higher than the SH-SY5 Y wild type cells.No toxic effect and no changes in cholestetol level were observed in the cells treated with 0.1 μmol/L lovastatin for 24 h.0.1 μmol/l lovastatin pretreatment of SH-SY5 Y cells with 24 h could improve the survival rate of cells and decreased Aβ dimer secretion.Conclusions:Lovastatin has a neuroprotective effect,which may be related to reducing the toxic Aβdimer synthesis.

关键词(KeyWords)： 洛伐他汀;β-淀粉样蛋白;淀粉样前体蛋白;阿尔兹海默病
lovastatin;β-amyloid protein;amyloid precursor protein;Alzheimer's disease

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81260173);; 教育部“长江学者和创新团队发展计划资助”(IRT13058);; 贵州省科技计划[黔科合重大专项字(2014)6008号];; 贵州省创新计划项目[黔教合协同创新中心(2014)06]

作者(Author): 赵亮,官志忠
ZHAO Liang,GUAN Zhizhong

DOI: 10.19367/j.cnki.1000-2707.2016.12.002

参考文献(References)：

• [1]Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics[J].Science,2002(5):353-356.
• [2]Reitz C,Brayne C,Mayeux R.Epidemiology of Alzheimer disease[J].Nat Rev Neurol,2011(3):137-152.
• [3]Megan E,Larson,Sylvain E,et al.Soluble Aβoligomer production and toxicity[J].J Neuchem,2012(1):125-139.
• [4]Kellick KA,Bottorff M,Toth PP,et al.A clinician's guide to statin drug-drug interactions.J Clin Lipidol,2014(1):30-46.
• [5]Willey JZ,Elkind MS.3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases.Arch Neurol,2010(9):1062-1067.
• [6]An Y,Qi XL,Pei JJ,et al.Amyloid precursor protein gene mutated at Swedish 670/671 sites in vitro induces changed expression of nicotinic acetylcholine receptors and neurotoxicity[J].Neurochem Int,2010(6):647-654.
• [7]Fukuda T,Takeda S,Xu R,et al.Sema3A regulates bone-mass accrual through sensory innervations[J].Nature,2013(4):490-493.
• [8]World Health Organization(WHO).Dementia:a public health priority.Alzheimer’s Disease Population and Country Statistical Analysis.Available from:http://www.who.intmental_health/neurology/dementia/en,2014.
• [9]Aisen P,Schneider L,Cummings J.Symptomatic and non-amyloid/tau based pharmacologic treatment for Alzheimer’s disease;in Selkoe D,Mandlekow E,Holtzman D(eds):The Biology of Alzheimer’s Disease[M].New York:Cold Spring Harbor Laboratory Press,2012(4):511-526.
• [10]Brian S,Appleby DN,Nicholas MA.Review:Treatment of Alzheimer’s Disease Discovered in Repurposed Agents[J].Dement Geriatr Cogn Disord,2013(1):1-22.
• [11]Williams PT.Lower risk of Alzheimer's disease mortality with exercise,statin,and fruit intake[J].J Alzheimers Dis,2015(4):1121-1129.
• [12]Butterfield DA,Barone E,Mancuso C.Cholesterol-independent neuroprotective and neurotoxic activities of statins:perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders[J].Pharmacol Res,2011(3):180-186.
• [13]Miida T,Hirayama S,Nakamura Y.Cholesterol-independent effects of statins and new therapeutic targets:ischemic stroke and dementia[J].J Atheroscler Thromb,2004(5):253-264.
• [14]Pahan K,Sheikh FG,Namboodiri AM,et al.Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes,microglia,and macrophages[J].J Clin Invest,1997(11):2671-2679.
• [15]Tong XK,Nicolakakis N,Fernandes P,et al.Simvastatin improves cerebrovascular function and counters soluble amyloid-beta,inflammation and oxidative stress in aged APP mice[J].Neurobiol Dis,2009(3):406-414.
• [16]Feldman HH,Doody RS,Kivipelto M,et al.Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease:LEADe[J].Neurology,2010(12):956-964.
• [17]Shepardson NE,Shankar GM,Selkoe DJ.Cholesterol and Statins in Alzheimer’s Disease:II.Review of Human Trials and Recommendations[J].Arch of Neurol,2011(11):1385-1392.
• [18]Kemppainen S,Hamalainen E,Miettinen PO,et al.Behavioral and neuropathological consequences of transient global ischemia in APP/PS1 Alzheimer model mice[J].Behav Brain Res,2014(1):15-26.
• [19]Mucke L,Masliah E,Yu Q,et al.High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice:synaptotoxicity without plaque formation[J].Neuroscience,2000(11):4050-4058.
• [20]Selkoe DJ.Soluble oligomers of the amyloidβ-protein mpair synaptic plasticity and behavior[J].Behav Brain Res,2008(1):106-113.
• [21]Yankner BA,Lu T.Amyloidβ-protein toxicity and the pathogenesis of Alzheimer disease[J].Biol Chem,2009(8):4755-4759.
• [22]Mucke L,Selkoe DJ.Neurotoxicity of amyloidβ-protein:synaptic and network dysfunction[J].Cold Spring Harb Perspect Med,2012(7):338.
• [23]Ganesh M.Shankar,Shaomin Li,et al.Amyloidβ-Protein Dimers Isolated Directly from Alzheimer Brains Impair Synaptic Plasticity and Memory[J].Nat Med,2008(8):837-842.

文章评论(Comment)：